医渡科技港股市值62.12亿港元，在医疗服务Ⅱ行业中排名第10。主要指标见下表： 2月27日，医渡科技(02158.HK)再度实施股份回购，当日以每股约5.99港元的价格回购32.2万股，总耗资 近200万港元。截至目前，公司年内已完成19次回购，累计斥资已超7600万港元，以连贯动作彰显对自 身长期价值与AI医疗行业前景的坚定信心。 截至2026年2月27日收盘，医渡科技(02158.HK)报收于5.97港元，上涨0.84%，成交量380.13万股，成交 额2274.38万港元。投行对该股的评级以跑赢行业(OUTPERFORM)为主，近90天内共有1家投行给出跑 赢行业(OUTPERFORM)评级，近90天的目标均价为6.8港元。中金公司最新一份研报给予医渡科技跑赢 行业(OUTPERFORM)评级，目标价6.8港元。 机构评级详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

截至2026年2月24日收盘，希玛医疗(03309.HK)报收于1.56港元，上涨0.65%，成交量28.6万股，成交额 44.38万港元。投行对该股关注度不高，90天内无投行对其给出评级。 希玛医疗(03309.HK)发布公告，于2026年2月24日斥资31.12万港元回购20万股。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 希玛医疗港股市值18.78亿港元，在医疗服务Ⅱ行业中排名第17。主要指标见下表： ...

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback of 140,000 shares at a total cost of HKD 1.9939 million, with a buyback price range of HKD 14.22 to 14.27 per share [1] - As of the market close on February 12, 2026, Haijia Medical's stock price was HKD 14.27, reflecting a decline of 1.11%, with a trading volume of 2.1016 million shares and a total transaction value of HKD 30.0401 million [1] - The stock is primarily rated as "Hold" by investment banks, with one bank providing a "Hold" rating in the last 90 days and a target price of HKD 13.5 [1] Group 2 - Haijia Medical has a market capitalization of HKD 8.898 billion and ranks 6th in the medical services sector [2]

Group 1 - The core viewpoint of the article highlights the launch of the "Spring Festival Health Guarantee Action" by Ping An Good Doctor to meet the health needs of the public during the Chinese New Year, emphasizing the company's commitment to providing continuous healthcare services [1] - The initiative includes a service network that covers "to line, to hospital, to home, and to enterprise," offering three categories of services and nine measures to ensure comprehensive health protection for the public [1] - The stock rating for Ping An Good Doctor is predominantly "buy," with two investment firms issuing buy ratings in the last 90 days, and the average target price set at HKD 20.14 [1] Group 2 - Ping An Good Doctor has a market capitalization of HKD 30.109 billion and ranks fourth in the medical services sector [2] - The latest report from CITIC Securities assigns a buy rating to Ping An Good Doctor with a target price of HKD 21 [1][2]

高盛发布研报称，将泰格医药(03347.HK)2025至2027年盈利预测分别下调29%、上调2%及上调2%，将 泰格医药H股目标价由63.4港元微升至66.4港元，泰格医药A股(300347.SZ) 目标价由78.7元人民币升至 82.5元人民币，均予"买入"评级。 投行对该股关注度不高，90天内无投行对其给出评级。 泰格医药港股市值58.83亿港元，在医疗服务Ⅱ行业中排名第12。主要指标见下表： | 指标 | 泰格医药 | 医疗服务 行业平均 | 行业排名 | | --- | --- | --- | --- | | ROE | 1.45% | 1.62% | 32 60 | | 港股流通市值 | 58.83 Z | 85.19亿 | 12 60 | | 营业收入 | 64.95 乙 | 39.01亿 | 7 60 | | 净利率 | 11.16% | -963.25% | 12 60 | | 毛利率 | 30.09% | 41.13% | 32 60 | | 负债率 | 15.93% | 74.33% | 8 60 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010434571030 ...

Group 1 - Citi has initiated a 90-day upward catalyst observation for Tigermed (03347.HK) with a target price of HKD 73 and a "Buy" rating [1] - Tigermed will participate in a healthcare conference in the U.S. and is expected to share optimistic industry trends and 2026 outlook due to strong performance in China's innovative drug research and a recovering funding environment [1] - The company is set to release its 2025 performance in March and provide guidance for 2026, with an anticipated 44% growth in operating profit by 2026 [1] Group 2 - As of January 14, 2026, Tigermed's stock closed at HKD 53.0, down 0.93%, with a trading volume of 3.6978 million shares and a turnover of HKD 199 million [1] - Tigermed's market capitalization is HKD 6.587 billion, ranking 12th in the healthcare services sector [1] - Key performance indicators for Tigermed compared to industry averages are as follows: ROE at 1.45% (industry average 1.62%), market capitalization at HKD 6.587 billion (industry average HKD 8.771 billion), revenue at HKD 6.495 billion (industry average HKD 3.901 billion), net profit margin at 11.16% (industry average -963.25%), gross margin at 30.09% (industry average 41.13%), and debt ratio at 15.93% (industry average 74.33%) [1]

Core Viewpoint - Haijia Medical (06078.HK) announced a general authorization for share repurchase at the upcoming annual general meeting on June 27, 2025, allowing the company to repurchase up to 61.8499 million shares, representing 10% of the total issued shares as of the meeting date [1] Group 1 - The company’s stock closed at HKD 11.63 on December 15, 2025, with an increase of 0.26% and a trading volume of 4.5822 million shares, resulting in a turnover of HKD 53.1235 million [1] - The investment banks predominantly rate the stock as a buy, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for Haijia Medical [1] Group 2 - Haijia Medical has a market capitalization of HKD 7.175 billion and ranks 7th in the medical services sector II [1] - Key performance indicators for the company are summarized in the accompanying table [1]

Core Viewpoint - Goldman Sachs maintains a "Neutral" rating on Alibaba Health (00241.HK) following the release of its mid-term results for the fiscal year ending September 2026, citing structural benefits from the outflow of original prescription drugs from hospital channels and accelerated online drug penetration [1] Financial Performance - Alibaba Health's revenue forecast for fiscal years 2026 to 2028 has been slightly adjusted to a growth of 2% to 4%, with corresponding adjustments to the adjusted net profit forecast also increased by 2% to 4% [1] - The target price has been raised from HKD 4.7 to HKD 5.2 based on a projected 28 times price-to-earnings ratio for its pharmacy and medical services business in 2027 [1] Market Position - As of December 2, 2025, Alibaba Health's stock closed at HKD 5.45, down 1.09%, with a trading volume of 77.95 million shares and a turnover of HKD 425 million [1] - The market capitalization of Alibaba Health is HKD 89.123 billion, ranking second in the medical services sector [2] Institutional Ratings - Recent ratings from various investment banks include: - Huatai Securities: Buy rating with a target price of HKD 6.08 [1] - Guosen Securities: Outperform rating [1] - CICC: Outperform rating with a target price of HKD 7.10 [1] - CITIC Securities: Awaiting rating with a target price of HKD 9.60 [1] Key Financial Metrics - Return on Equity (ROE): 8.22%, significantly higher than the industry average of 0.02% [2] - Revenue: HKD 28.344 billion, ranking third in the industry [2] - Net Profit Margin: 5.39%, compared to an industry average of -843.36% [2] - Debt Ratio: 24.76%, much lower than the industry average of 74.15% [2]

Group 1 - The core point of the article is that Universal Medical (02666.HK) has received approval from the China Securities Regulatory Commission to issue a public corporate bond in China with a total principal amount of up to RMB 8 billion [1] - The remaining balance of the corporate bond is RMB 5.4 billion, and the bond will be issued in tranches, with the fourth tranche not exceeding RMB 1 billion [1] - The stock price of Universal Medical closed at HKD 6.28, with a 0.32% increase, and the trading volume was 2.293 million shares, amounting to HKD 14.314 million [1] Group 2 - Universal Medical has a market capitalization of HKD 12.609 billion, ranking 5th in the healthcare services sector [2] - Key financial metrics include a Return on Equity (ROE) of 12.39%, revenue of RMB 14.701 billion, and a net profit margin of 17.61% [2] - The company has a debt ratio of 73.38%, which is slightly lower than the industry average of 74.15% [2]

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 160,000 shares at a total cost of HKD 277,200, with a buyback price ranging from HKD 1.72 to HKD 1.74 per share [1] Company Summary - As of November 26, 2025, Hema Medical's stock closed at HKD 1.74, reflecting a 0.58% increase with a trading volume of 320,000 shares and a turnover of HKD 553,000 [1] - The market capitalization of Hema Medical is HKD 2.142 billion, ranking 15th in the medical services sector [1] Financial Metrics - Return on Equity (ROE): -6.36%, compared to the industry average of -0.02%, ranking 39th in the sector [1] - Market Capitalization: HKD 2.142 billion, while the industry average is HKD 7.938 billion, ranking 15th [1] - Revenue: HKD 1.935 billion, with the industry average at HKD 3.832 billion, ranking 15th [1] - Net Profit Margin: 5.95%, significantly better than the industry average of -843.36%, ranking 25th [1] - Gross Profit Margin: 31.12%, compared to the industry average of 39.76%, ranking 28th [1] - Debt Ratio: 29.8%, much lower than the industry average of 74.15%, ranking 21st [1]